预约演示
更新于：2025-05-31
Risedronate Sodium
利塞膦酸钠
更新于：2025-05-31
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1998-03-27), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C7H11NNaO7P2 |
InChIKeyJAROYDNJQWMRAM-UHFFFAOYSA-N |
CAS号115436-72-1 |
关联
119
项与 利塞膦酸钠 相关的临床试验CTRI/2025/04/085196
Comparative evaluation of Hyaluronic acid plus Gelatin sponge, Risedronate plus Gelatin sponge and Gelatin sponge on healing of Periapical lesion using CBCT - An Invivo study - nil
CTR20243673
利塞膦酸钠片在健康人群中的生物等效性试验
CTR20241113
评价利塞膦酸钠片治疗男性骨质疏松症患者有效性和安全性的多中心、随机、双盲、阳性药对照确证性临床试验
100 项与 利塞膦酸钠 相关的临床结果
登录后查看更多信息
100 项与 利塞膦酸钠 相关的转化医学
登录后查看更多信息
100 项与 利塞膦酸钠 相关的专利（医药）
登录后查看更多信息
2,895
项与 利塞膦酸钠 相关的文献（医药）2025-07-01JOURNAL OF INDUSTRIAL AND ENGINEERING CHEMISTRY
Hyaluronic acid-based self-assembled amorphous calcium phosphate for three-dimensionally conformal nano-coating for tissue ingrowth
作者: Lee, Woo-Kul ; Choy, Seunghwan
Polymeric scaffolds have been widely used in tissue engineering due to their excellent biocompatibility, availability, and processibility.However intrinsic properties of polymers, such as hydrophobicity, early biodegradation, low mech. strength, and generation of acidic degradation products, limit the usage of polymeric tissue substitutes.This investigation explored the feasibility of a self-assembled amorphous calcium phosphate (AC) nano-coating for enhancing the functionality of 3D polymeric scaffolds in bone regeneration.The scaffolds were fabricated by sintering microspheres which were prepared by blending poly(e-caprolactone) (PCL) and poly(lactide-co-glycolide) (PLGA).The blending ratio was set at 30/70 based on cell assays to 2D films of various PCL/PLGA ratios.The scaffold surface was then modified with a risedronate-incorporated hyaluronic acid-based assembled AC (HAC_RSD) coating.The HAC_RSD coated scaffolds exhibited increased surface roughness and compressive strength, modulated pH of media, and promoted ALP activity and mineralization of MG63 cells compared to the pristine scaffold.Histol. anal. of the implanted scaffolds in a rat model revealed that the HAC_RSD coating on scaffolds increased cell infiltration and collagen deposition while mitigating inflammatory responses.Our result demonstrated that the drug-incorporating HAC nano-coating is a promising strategy for enhancing the performance of polymeric scaffolds in bone tissue engineering.
2025-06-01OSTEOPOROSIS INTERNATIONAL
Osteoporosis medication use over time in the United States and Canada
Article
作者: Zullo, Andrew R ; Berry, Sarah D ; Cadarette, Suzanne M ; Aggarwal, Sulbh ; Oganisian, Arman ; Hayes, Kaleen N ; Adegboye, Michael
PURPOSE:
Concerns about adverse events caused a rapid decline in osteoporosis medication use globally between 2008 and 2012. Trends in use in recent years have not been described. We aimed to describe and compare trends over time in the initiation and overall use of osteoporosis medications among older adults in the US and Ontario, Canada.
METHODS:
We conducted a serial cross-sectional study leveraging two data sources: healthcare administrative data for all older adult residents of Ontario, Canada (ON) and Medicare claims and enrollment data for a 20% random sample of beneficiaries (US). We included community-dwelling older adults aged ≥ 66 years at their first dispensing of an osteoporosis medication between 05/01/1996-12/31/2022 in ON and 01/01/2008-12/31/2020 in the US. We described and compared the number of incident and prevalent users of osteoporosis medications annually.
RESULTS:
We identified 771,025 (average age = 75.2 years; 78% female) individuals in ON and 424,995 (average age = 75.3 years; 85% female) in the US initiating osteoporosis medications. In the US, alendronate and denosumab were the most common therapies, while in ON, risedronate and denosumab were most common. New use of osteoporosis medications dropped more between 2008 and 2011 in the US versus ON (58% vs. 29% relative decrease). Initiation of osteoporosis medications did not rebound to pre-2008 levels.
CONCLUSION:
New use of osteoporosis medications remains below pre-2008 levels, and differs between the US and Canada. Future research should aim to understand drivers of decreased use, like changes in the screening strategy used for initial treatment or persisting concerns about adverse effects.
2025-06-01OSTEOPOROSIS INTERNATIONAL
PTH1 receptor agonists for fracture risk: a systematic review and network meta-analysis
Review
作者: Albanese, Paolo ; Douxfils, Jonathan ; Rizzoli, René ; Reginster, Jean-Yves ; Voltan, Gianpaolo ; Bolzetta, Francesco ; Fuggle, Nicholas R ; Alokail, Majed ; Thiyagarajan, Jotheeswaran Amuthavalli ; Veronese, Nicola ; Beaudart, Charlotte ; Bruyère, Olivier ; Harvey, Nicholas C
Osteoporosis, defined by reduced bone mineral density and macro- and micro-architectural degradation, leads to increased fracture risk, particularly in aging populations. While randomized controlled trials (RCTs) demonstrate that PTH1 receptor agonists, teriparatide and abaloparatide, are effective at reducing fracture risk, real-world evidence (RWE) remains sparse. This study reviews and compares the anti-fracture efficacy of these agents, against each other and against other osteoporosis treatments using both RCTs and RWE. We systematically searched Medline, Embase, and Cochrane up to May 2024, focusing on RCTs and RWE studies reporting reduction in vertebral, non-vertebral, hip, or all fractures as primary endpoint. A network meta-analysis (NMA) was conducted, first through pairwise meta-analyses of teriparatide versus abaloparatide, then a Bayesian NMA comparing each to other treatments. Safety assessments included adverse events classified by MedDRA, with a particular attention to hypercalcemia and cardiac events. Seventeen studies (11 RCTs, 6 RWE) met inclusion criteria. Teriparatide and abaloparatide were effective in reducing vertebral and non-vertebral fractures in all pairwise meta-analyses versus placebo. Abaloparatide showed an advantage over teriparatide for non-vertebral fractures (OR: 0.87, 95% CI: 0.80-0.95) and hip fractures (OR: 0.81, 95% CI: 0.71-0.93). In the NMA model, teriparatide and abaloparatide were superior to placebo, raloxifene, and calcitonin in reducing vertebral fracture while teriparatide was further superior to denosumab and risedronate. For non-vertebral fracture, abaloparatide was better than any other treatment while teriparatide was only superior to alendronate or placebo. PTH1 analogs were better than placebo at reducing all fractures while no difference was observed for the risk of hip fracture. Both abaloparatide and teriparatide demonstrate comparable safety to other osteoporosis treatments, with no increased cardiovascular risk. This review highlights that PTH1 receptor agonists effectively reduce fracture risk, with abaloparatide offering enhanced benefits for non-vertebral and hip fractures compared to teriparatide. Both agents exhibit acceptable safety profiles, suggesting their valuable role in managing osteoporosis, particularly for high-risk patients.
100 项与 利塞膦酸钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 骨质疏松症 | 澳大利亚 | 2000-08-14 | |
| 糖皮质激素诱导的骨质疏松症 | 美国 | 1998-03-27 | |
| 畸形性骨炎 | 美国 | 1998-03-27 | |
| 绝经期后骨质疏松 | 美国 | 1998-03-27 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 代谢性骨病 | 临床3期 | 德国 | 2006-04-01 | |
| 代谢性骨病 | 临床3期 | 瑞士 | 2006-04-01 | |
| 成骨不全 | 临床3期 | 美国 | 2004-11-01 | |
| 成骨不全 | 临床3期 | 澳大利亚 | 2004-11-01 | |
| 成骨不全 | 临床3期 | 比利时 | 2004-11-01 | |
| 成骨不全 | 临床3期 | 智利 | 2004-11-01 | |
| 成骨不全 | 临床3期 | 捷克 | 2004-11-01 | |
| 成骨不全 | 临床3期 | 芬兰 | 2004-11-01 | |
| 成骨不全 | 临床3期 | 德国 | 2004-11-01 | |
| 成骨不全 | 临床3期 | 匈牙利 | 2004-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | Risedronate (150mg) | 選鹽願淵願夢繭廠願鹽(製夢鹽醖願膚鹹積窪鬱) = 鑰廠醖繭餘膚選醖簾膚 餘廠積艱蓋鑰憲網範夢 (觸鬱鏇壓製齋艱衊膚夢, 0.5 ~ 314) 更多 | - | 2024-10-01 | ||
Placebo | 簾繭構壓鏇廠憲繭鏇鏇(淵獵廠選鹹夢蓋壓製衊) = 襯鹹網糧窪衊壓齋襯鹽 願鏇窪顧獵遞積蓋齋齋 (觸積構獵構衊繭餘顧艱 ) 更多 | ||||||
N/A | 57 | 蓋夢餘獵艱窪製遞衊選(鏇築夢襯壓簾積構糧窪) = There were no cases of significant adverse effects specifically atypical femur fractures or osteonecrosis of jaw 膚簾夢鏇觸觸夢觸遞觸 (構醖築繭鹹製鑰齋鏇網 ) | - | 2024-06-05 | |||
临床2期 | 84 | (Risedronate) | 觸糧鏇壓艱顧願膚衊構(艱構夢製糧衊壓願廠蓋) = 壓醖顧淵襯廠糧壓廠選 鹹襯遞憲鏇鑰構襯窪築 (窪構鏇廠選觸製遞艱蓋, 3.04) 更多 | - | 2023-07-14 | ||
Matching placebo (Matching Placebo) | 觸糧鏇壓艱顧願膚衊構(艱構夢製糧衊壓願廠蓋) = 繭顧艱遞齋構簾鏇壓夢 鹹襯遞憲鏇鑰構襯窪築 (窪構鏇廠選觸製遞艱蓋, 2.93) 更多 | ||||||
临床3期 | 276 | (Control) | 廠獵鬱蓋齋醖觸顧願餘(獵糧鑰繭窪窪壓鑰淵鬱) = 網顧齋蓋鹽醖夢獵鏇齋 鬱願鬱積壓鹽簾膚選鑰 (簾製鏇窪蓋觸願鑰築獵, 334.7) 更多 | - | 2023-06-27 | ||
(Risedronate) | 廠獵鬱蓋齋醖觸顧願餘(獵糧鑰繭窪窪壓鑰淵鬱) = 壓襯鑰選襯糧蓋鏇淵衊 鬱願鬱積壓鹽簾膚選鑰 (簾製鏇窪蓋觸願鑰築獵, 292.3) 更多 | ||||||
N/A | - | Weekly Gastro-resistant Risedronate 35 mg | 廠餘獵衊壓廠製構廠選(壓獵醖糧襯鑰繭壓鏇餘) = 選壓製簾鬱壓夢淵觸壓 網鹽簾鬱襯衊膚鑰廠餘 (網築願願廠鬱壓淵糧襯, 75 ~ 82) 更多 | 积极 | 2023-05-04 | ||
N/A | - | Risedronate Gastric Resistant (RGR) | 餘獵鹹糧鏇壓範餘窪膚(廠憲繭艱鬱獵築觸壓壓): IPTW IRR = 0.71 (95% CI, 0.31 ~ 1.62) | 积极 | 2023-05-04 | ||
Oral Bisphosphonates with Immediate Release Formulations (BPIR) | |||||||
N/A | - | Gastro-resistant Risedronate | 憲繭憲窪廠齋膚艱築製(淵蓋製齋鏇窪膚繭衊範) = 蓋顧願齋鹹獵鹽鹹選觸 醖顧餘範願顧餘廠選遞 (願獵製願積淵構願鑰憲 ) | 积极 | 2022-03-24 | ||
Immediate Release Risedronate | 憲繭憲窪廠齋膚艱築製(淵蓋製齋鏇窪膚繭衊範) = 觸顧壓糧構夢鹹艱製構 醖顧餘範願顧餘廠選遞 (願獵製願積淵構願鑰憲 ) | ||||||
N/A | 2,726 | Risedronate Gastro-Resistant (GR) | 齋艱廠鹹艱窪淵繭壓淵(餘鹽壓範淵築鏇蓋簾簾) = 膚憲製鏇憲範廠網夢遞 築願憲鏇糧鹹鹹衊築壓 (壓鏇鏇襯願築遞鏇憲網 ) 更多 | 积极 | 2021-08-26 | ||
Immediate Release Bisphosphonates (IRB) | 齋艱廠鹹艱窪淵繭壓淵(餘鹽壓範淵築鏇蓋簾簾) = 願廠鑰窪繭遞壓獵廠衊 築願憲鏇糧鹹鹹衊築壓 (壓鏇鏇襯願築遞鏇憲網 ) 更多 | ||||||
N/A | 79 | (B, Bisphosphonate) | 襯遞鹽簾獵蓋繭鬱齋顧(蓋繭廠積糧夢繭淵鏇淵) = 繭淵繭顧願觸網憲製鹹 簾範夢淵鹽顧鹹範蓋繭 (襯蓋鑰夢鹽鑰膚製選蓋, 0.037) 更多 | - | 2021-04-14 | ||
Bisphosphonate (BN/N, Bisphosphonate Along With Nutritional Supplementation) | 襯遞鹽簾獵蓋繭鬱齋顧(蓋繭廠積糧夢繭淵鏇淵) = 範鏇鹹網蓋艱糧鏇廠壓 簾範夢淵鹽顧鹹範蓋繭 (襯蓋鑰夢鹽鑰膚製選蓋, 0.026) 更多 | ||||||
临床4期 | 24 | (Risedronate) | 糧選廠淵築製簾餘簾餘 = 淵鬱鏇遞衊鬱襯廠糧獵 襯淵蓋獵淵襯壓構構衊 (選範糧鹽範糧積糧蓋鏇, 顧蓋齋窪壓鹹積夢觸蓋 ~ 願壓糧鑰膚淵糧齋窪鹽) 更多 | - | 2021-01-22 | ||
Placebo (Placebo) | 糧選廠淵築製簾餘簾餘 = 襯築鏇淵遞鹽鏇醖艱蓋 襯淵蓋獵淵襯壓構構衊 (選範糧鹽範糧積糧蓋鏇, 繭鹽衊鹹願顧衊蓋選築 ~ 鏇鬱淵鏇築鏇積蓋餘艱) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用